Stroke Thrombolysis: Save a Minute, Save a Day
暂无分享,去创建一个
Geoffrey A. Donnan | Leonid Churilov | Mahsa Keshtkaran | Atte Meretoja | Stephen M. Davis | Turgut Tatlisumak | Mark W. Parsons | Jeffrey L. Saver | M. Kaste | A. Meretoja | G. Donnan | J. Saver | S. Davis | L. Churilov | T. Tatlisumak | M. Parsons | Markku Kaste | M. Keshtkaran | S. Davis
[1] Jin-Moo Lee,et al. Reducing Door-to-Needle Times Using Toyota’s Lean Manufacturing Principles and Value Stream Analysis , 2012, Stroke.
[2] S. Johnston. The Economic Case for New Stroke Thrombolytics , 2010, Stroke.
[3] K. Welch,et al. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1997, Archives of neurology.
[4] Leonid Churilov,et al. Thrombolysis for acute stroke in Australia: outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002–2008) , 2010, The Medical journal of Australia.
[5] V. Demarin,et al. Factors Influencing In-Hospital Delay in Treatment With Intravenous Thrombolysis , 2012, Stroke.
[6] S. Fagan,et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. , 1999, Neurology.
[7] M. Kaste,et al. Does Time of Day Or Physician Experience Affect Outcome of Acute Ischemic Stroke Patients Treated with Thrombolysis? a Study from Finland , 2012, International journal of stroke : official journal of the International Stroke Society.
[8] Jeffrey L Saver,et al. Quantifying the Value of Stroke Disability Outcomes: WHO Global Burden of Disease Project Disability Weights for Each Level of the Modified Rankin Scale , 2009, Stroke.
[9] Atte Meretoja,et al. Reducing in-hospital delay to 20 minutes in stroke thrombolysis , 2012, Neurology.
[10] M. Kaste,et al. Ultraearly Thrombolysis in Acute Ischemic Stroke Is Associated With Better Outcome and Lower Mortality , 2010, Stroke.
[11] M. Wintermark,et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[12] Joanna M. Wardlaw,et al. Cost-Effectiveness of Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke Assessed by a Model Based on UK NHS Costs , 2004, Stroke.
[13] B. Kissela,et al. Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial , 2012, Stroke.
[14] A. Rabinstein,et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2008 .
[15] J. Saver,et al. Years of Disability-Adjusted Life Gained as a Result of Thrombolytic Therapy for Acute Ischemic Stroke , 2010, Stroke.
[16] M. Kaste,et al. Off-Label Thrombolysis Is Not Associated With Poor Outcome in Patients With Stroke , 2010, Stroke.
[17] Alan D. Lopez,et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[18] Klaus Fassbender,et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial , 2012, The Lancet Neurology.
[19] Maarten G Lansberg,et al. Cost-Effectiveness of Tissue-Type Plasminogen Activator in the 3- to 4.5-Hour Time Window for Acute Ischemic Stroke , 2011, Stroke.
[20] J. Mar,et al. Cost-Effectiveness Analysis of Thrombolytic Treatment for Stroke , 2005, Cerebrovascular Diseases.
[21] P. Sandercock,et al. How many Patients might Receive Thrombolytic Therapy in the Light of the ECASS-3 and IST-3 Data? , 2010, International journal of stroke : official journal of the International Stroke Society.
[22] Joanna Wardlaw,et al. Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial , 2009, The Lancet Neurology.
[23] Bernadette A. Thomas,et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[24] M Frankel,et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke , 1998, Neurology.
[25] J. Fox-Rushby,et al. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. , 2001, Health policy and planning.
[26] Lorenz Breuer,et al. Avoiding in Hospital Delays and Eliminating the Three-Hour Effect in Thrombolysis for Stroke , 2011, International journal of stroke : official journal of the International Stroke Society.
[27] Adrian F Hernandez,et al. Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.
[28] J. Saver. Time Is Brain—Quantified , 2006, Stroke.
[29] M. Endres,et al. Prehospital thrombolysis in acute stroke , 2013, Neurology.
[30] Mette Kjølby,et al. Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke , 2007, Stroke.
[31] Eric E. Smith,et al. Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.
[32] C. Marra,et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. , 2001, PharmacoEconomics.
[33] Werner Hacke,et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.
[34] Atte Meretoja,et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months , 2013, Neurology.
[35] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[36] Adrian F Hernandez,et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. , 2013, JAMA.
[37] M. Kaste,et al. Pre‐ and in‐hospital intersection of stroke care , 2012, Annals of the New York Academy of Sciences.
[38] T. Saifee,et al. Prehospital thrombolysis in acute stroke: Results of the PHANTOM-S pilot study , 2013, Neurology.
[39] Alan D. Lopez,et al. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.